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The objective was to develop a set of “best practices” for use as a primer for those interested in entering
the clinical trials ﬁeld for lifestyle diet and/or exercise interventions in osteoarthritis (OA), and as a set of
recommendations for experienced clinical trials investigators. A subcommittee of the non-pharmacologic
therapies committee of the OARSI Clinical Trials Working Group was selected by the Steering Committee
to develop a set of recommended principles for non-pharmacologic diet/exercise OA randomized clinical
trials. Topics were identiﬁed for inclusion by co-authors and reviewed by the subcommittee. Resources
included authors' expert opinions, traditional search methods including MEDLINE (via PubMed), and
previously published guidelines. Suggested steps and considerations for study methods (e.g., recruitment
and enrollment of participants, study design, intervention and assessment methods) were recom-
mended. The recommendations set forth in this paper provide a guide from which a research group can
design a lifestyle diet/exercise randomized clinical trial in patients with OA.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
The diet/exercise subcommittee, a division of the non-
pharmacologic therapies committee of the OARSI Clinical Trials
Working Group, was selected by the Steering Committee. A chair
was appointed and the group charged to develop a set of “best
practices” for use as a primer for those interested in entering the
clinical trials ﬁeld for lifestyle diet/exercise therapies in osteoar-
thritis (OA), and as a set of recommendations for experienced
clinical trials investigators. The development of these recommen-
dations for the design and conduct of lifestyle diet/exercise in-
terventions for people with lower extremity OA beganwith a series
of teleconferences and email interactions among the subcommittee
members. The subcommittee developed and reached consensus on
a set of recommended principles for lifestyle diet and/or exercise
OA RCTs. Identiﬁed topics for inclusionwere assigned to co-authorsto: S.P. Messier, J.B. Snow
xercise Science, Wake Forest
ternational. Published by Elsevier Ldepending on their areas of expertise. Resources used to write the
ﬁrst draft included authors'expert opinions, traditional search
methods including MEDLINE (via PubMed), and previously pub-
lished guidelines1. Hence, the recommendations are supported by a
combination of published clinical research and best judgment of
the subcommittee members. Subsequent drafts were edited by the
subcommittee and a ﬁnal version submitted to the Journal for re-
view and editing. The published draft was approved by all sub-
committee members and the Steering Committee.
Qualiﬁcations of the study group
Dr Messier and his clinical trials research group have advanced
non-pharmacologic treatment for knee OA in four large-scale
clinical trials: Fitness Arthritis in Seniors Trial (FAST), Arthritis
Diet and Activity Promotion Trial (ADAPT), Intensive Diet and
Exercise for Arthritis (IDEA), and the ongoing Strength Training for
Arthritis Trial (START). Dr Callahan has completed ﬁve trials of
physical activity or behavioral lifestyle interventions in over 1700
participants with arthritis and joint pain in Johnston, Haywood,
and 40 other rural and urban North Carolina counties. Shetd. All rights reserved.
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Health, Area Agency on Aging, Senior Centers, churches, univer-
sities, AHEC, local physicians, and industry to conduct these
community studies. Dr Golightly's research involves the long-
term effects of musculoskeletal injury and disorders of the lower
extremity. These long-term consequences include OA, pain,
disability, identifying modiﬁable risk factors for injury and OA, and
developing non-pharmacologic/non-surgical treatment and pre-
vention strategies. Dr Keefe's research evaluates the efﬁcacy of
cognitive-behavioral treatments and exercise interventions for
arthritis pain. He is a leading authority on the use of pain coping
skills interventions to improve clinical outcomes in older adults
with OA.
Levels of lifestyle modiﬁcation clinical trials for OA
The categories developed for clinical trials research have pri-
marily been used to describe the stages involved in conducting
pharmacological studies. We have adapted these categories to
describe exercise and dietary therapy (i.e., weight loss) clinical
trials in which behavioral techniques are used to promote lifestyle
diet and exercise changes (note: the terms lifestyle modiﬁcation
trials and behavioral trials are used interchangeably). Safety con-
cerns in behavioral trials are minimal compared to pharmacologic
trials; hence, linear progression from phase 1 to phase 3 trials may
not be necessary in all cases.
Phase 1 trials
Phase 1 behavioral intervention trials typically test the feasi-
bility, acceptability, and safety of intervention and assessment
protocols. Feasibility and acceptability is, in part, evaluated by
successful overall accrual, high participant retention, high ﬁdelity
by interventionists to the intervention protocol, and high adher-
ence by patients to an intervention. In addition, feedback from
patients about their experience with assessment and intervention
procedures is often obtained in formative interviews, focus groups,
or responses to questionnaires. This feedback can play a crucial role
in shaping and reﬁning the assessment protocols and the exercise
and/or weight loss protocols to be used in a larger Phase 2 trial.
Safety is evaluated by tracking adverse events (AEs) occurring over
the Phase 1 trial. Evaluation of efﬁcacy is not the primary purpose
of Phase 1 trials. A Phase 1 trial cannot adequately or deﬁnitively
address the effects of behavioral interventions. Data from Phase 1
behavioral trials may or may not provide preliminary effect size
data for use in power and sample size calculations for a subsequent
Phase 2 trial. For multicenter behavioral trials, these smaller pilot
studies often help identify problems in data collection or in the
intervention protocol and ways to solve them. They also are valu-
able in developing and testing strategies for facilitating study co-
ordination across sites (e.g., weekly telephone calls for study
investigators; monthly calls for the entire study team; tracking of
patient progress). Multisite Phase 1 behavioral trials also provide
valuable opportunities to develop and test recruitment strategies,
protocols for standardizing data collection, data management, and
randomization. The end result is a manual of operations (MOOP)
that can be used to guide a larger andmore deﬁnitive Phase 2 study.
Phase 1 trials may also contain a dose-ﬁnding component.
Escalating dose trials are desirable for initial evaluation of the in-
tensity of treatment needed (e.g., intensity of exercise or intensity
of a diet intervention). Initially, the presence of comorbid condi-
tions should be minimized; later studies may target special pop-
ulations, such as individuals taking concomitant medication or
populations more typical of clinical practice (e.g., those with mul-
tiple comorbid conditions). Phase 1 trials may be performed innormal volunteers or in a patient population appropriate for the
target indication.
Testing the feasibility and tolerability of high intensity strength
training in older adults with knee OA is an example of a Phase 1
behavioral trial. The effectiveness of intense strength training ex-
ercise to improve OA symptoms, slow disease progression, and
affect underlying mechanisms has not been examined due to the
unsubstantiated belief that intense strength training might exac-
erbate symptoms. A Phase 1 trial would provide investigators with
the experience of workingwith patients under these conditions; for
example how do exercise interventionists adjust strength workouts
on days when intense exercise elicits too much pain? It also would
provide critical information onwhether patients with chronic knee
pain are able to tolerate long term intensive strength training. Such a
trial would include a smaller sample size and shorter intervention
than a more deﬁnitive, subsequent clinical trial.
Phase 2 trials
Behavioral Phase 2 trials are randomized trials designed to test
efﬁcacy2 and aim to test whether an intervention works and is safe
under optimal conditions. To optimize treatment effects, Phase 2
trials carefully screen patients to ensure they meet enrollment
criteria and are free of comorbid conditions that could inﬂuence the
study outcomes. These studies use assessment and treatment pro-
tocols that are highly standardized and use materials and pro-
cedures developed in Phase 1 trials (e.g., treatment manual, patient
handouts, and interventionist training procedures). Phase 2
behavioral trials typically rely on experienced interventionists who
receive extensive initial training in the study protocol. To prevent
interventionist drift (i.e., deviation over time of an interventionist's
understanding or implementation of a treatment) and enhance
treatment ﬁdelity, these trials feature ongoing supervision/training
of interventionists and monitoring of treatment sessions. Phase 2
trials are usually powered to detect clinically meaningful as well as
statistically signiﬁcant differences between intervention and con-
trol conditions. As an alternative to a usual care control condition,
many Phase 2 behavioral trials include a comparison/control con-
dition that provides a control for the effects of therapist time and
attention (e.g., attention control, education/information compari-
son condition). Blinding to reduce bias in a study occurs when in-
formation about the patient's group assignment is concealed from
the researchers (assessors collecting outcome data and the in-
terventionists delivering the treatment) and/or from the patient
(i.e., patient does not knowhis/her group assignment) until after the
trial is completed. If either the researcher or the patient is blinded it
is termed a single blinded study; double blinding occurs when the
researcher and patient are blinded. While blinding the assessors is
typically feasible in exercise and/or diet trials, blinding the inter-
ventionist delivering the exercise and/or diet treatment and the
patients randomized to the treatment groups is generally not
possible; hence, most exercise and diet trials are assessor-blinded
studies with the interventionists having no data collection re-
sponsibilities and the patients explicitly instructed not to reveal
their group assignment to the assessors during follow-up testing.
Phase 2 trialswould rely on the preliminary data gathered froma
Phase 1 trial. Sample sizes depend on power estimates, but are
usually in the range of 100e150 per group and the duration of the
interventions is typically 3monthse18months for participantswith
established knee OA (Kellgren-Lawrence (KL) scores of 2, 3, or 4).
Phase 3 trials
Phase 3 trials are intended to demonstrate deﬁnitively the efﬁ-
cacy of a lifestyle diet and/or exercise intervention in large groups of
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mental interventions as well as to monitor adverse effects, and to
collect information that will allow the interventions to be used
safely. A Phase 3 trial would utilize treatment procedures and ma-
terials developed and reﬁned in a Phase 2 trial. There should be only
one target joint or joint site in a single trial, though participantsmay
have involvement of other much less symptomatic joints. Infor-
mation on the effects on these joints or regions of the body could be
collected as secondary or experimental outcomes. These studies are
designed to establish that the behavioral intervention works (by
comparing to usual care), to further deﬁne safety, and to recom-
mend the intervention for clinical use. Sample size and study
duration should be calculated a priori to assure that participantswill
be followed for a sufﬁcient timeperiod to detect a clinically relevant,
as well as a statistically signiﬁcant, difference between treatment
and control groups with respect to efﬁcacy. Since participants in
behavioral exercise and diet trials are aware of their group assign-
ment, placebo effects in the control group are generally much
smaller than in pharmacologic trials. Because expectation bias,
positive for patients assigned to the intervention group, and nega-
tive for those assigned to the control group, could confound inter-
pretation of the results, measures of treatment credibility and
outcome expectations should be taken at the start of a trial. Analyses
of these data can help in determining whether expectations and
credibility are similar for the different treatment arms of the study.
The use of an attention control group inwhich patients are provided
attention through face-to-face educational information sessions
throughout the course of the study on topics such as healthy living
or healthy aging also may attenuate such bias. The number of pa-
tients and length of time to assess safety should follow the recom-
mendation for the disease being studied. Positive results fromPhase
3 trials usually impact standard-of-care practices.
Pragmatic trials
Pragmatic trials are designed to evaluate the effectiveness of
behavioral interventions in real-life routine practice conditions;
whereas Phase 2 and Phase 3 efﬁcacy trials aim to test whether an
intervention works under optimal conditions among highly
selected participants (i.e., high internal validity). By using broader
inclusion criteria and relying on usual clinical staff or less highly
trained staff to deliver treatment, pragmatic trials are more likely to
produce results that can be generalized and applied in routine
practice settings (high external validity). Pragmatic trials attempt to
answer the question: Does this intervention work under usual
conditions? Special strategies to maintain or improve compliance
are either limited or not used. Selection of participants for the study
is less stringent, reﬂecting real-world clinical practice by including
most individuals that have the condition (e.g., chronic knee pain)
and excluding those for which there are pertinent safety concerns
(e.g., anticipate serious adverse events (SAEs) with the treatment,
presence of comorbidities that complicate carrying out of
intervention).
Few trials are purely pragmatic in design; rather there is a
continuum between pragmatic and efﬁcacy trials2. For example, a
purely pragmatic trial onweight loss would involve very few, if any,
follow-up interventionist meetings. However, there is a strong
relationship between the frequency of contacts and the success of
the weight loss intervention3,4. If the investigators are convinced
very limited patient contacts will fail to reach the intended weight
loss goal and inevitably result in a failed trial, then they may
consider including more patient contacts, an efﬁcacy trial charac-
teristic. If the trial is positive, then the frequency of patient contacts
would be included in standard-of-care guidelines. An excellent
primer on pragmatic trials can be found in Thorpe et al.2.When two or more treatments have demonstrated clinical and
statistical efﬁcacy in Phase 2 or preferably Phase 3 trials, a com-
parison of the relative efﬁcacy of these interventions can be tested
in a comparative effectiveness trial. This could be Phase 3 or
Pragmatic in design. The results may prove beneﬁcial to clinicians
in deciding which of the established treatments is best, or which
works best with certain patients, or the mechanisms by which the
treatments exert their effects.
Considerations for entering OA patients into behavioral diet
and exercise intervention trials
This section addresses the parts of the protocol that focus on
recruiting and enrolling participants for a behavioral diet and/or
exercise intervention trial for patients with OA, as well as baseline
data that are necessary for describing the participants. Reasons for
selection of participants should be clearly established in advance,
making sure that inclusion and exclusion criteria essential to the
study are well-deﬁned.
Overview of the study protocol
The protocol should include background information, speciﬁc
objectives and research questions, the design of the study, and the
organization of the trial. Study design features consist of inclusion
and exclusion criteria for the study population, estimates of sample
size, methods for recruitment (e.g., referral from healthcare pro-
viders, advertisements, registries), enrollment procedures
(informed consent, screening for eligibility, baseline assessment,
and intervention allocation), description and schedule for the
intervention, description and schedule for follow-up visits, primary
and secondary outcome measures, safety assessment (methods for
reporting AEs), a data analysis plan, and a termination policy. The
protocol should describe the organization of the trial, such as the
participating investigators, the clinical center(s), data coordinating
center (in the case of a multi-center trial), and data safety moni-
toring board (DSMB). The DSMB is a group (usually three or more
members) of clinicians, scientists, and biostatisticians that are in-
dependent of the group conducting the clinical trial and are
knowledgeable about the disease or condition being studied. This
group meets periodically (at least once per year) to review safety
records including adverse and SAEs, and unblinded interim results
such as recruitment, adherence and retention rates. The DSMB has
the power to recommend termination of the study based on these
results. Adverse and SAEs are immediately reported to the DSMB
and the institutional review board (IRB) for evaluation. Many life-
style modiﬁcation interventions are considered low risk for the
participants. In such cases, the granting agency may assign a single
safety ofﬁcer or require only a written safety monitoring plan in
place of a DSMB.
The protocol should be developed prior to participant enroll-
ment and major changes are generally not made during the trial.
Any changes must meet with IRB approval and also be approved
by the study sponsor. Most journals now require registration of
trials prior to participant enrollment for study results to be
considered for publication, and sponsors, such as the National
Institutes of Health, require registration of their supported trials.
Trials may be registered at sites like ClinicalTrials.gov, and in-
formation about study design, study population, outcome vari-
ables, and intervention and control arms of the study should be
described. A link to the protocol may be included. The protocol
also should address elements suggested by the Consolidated
Standards of Reporting Trials (CONSORT) statement (http://www.
consort-statement.org/) and the CONSORT extension for non-
pharmacologic treatments5,6. These statements provide
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endorsed by numerous medical journals. Further discussion of
the CONSORT statement can be found in the Statistical Overview
section of this issue.
All the information regarding the study protocol and conduct of
the trial should be included in a MOOP. In behavioral intervention
trials, the MOOP should include a treatment manual that provides
detail on each treatment session and a description of procedures for
interventionist training, ongoing supervision, and monitoring of
the quality of treatment. The MOOP likewise should thoroughly
describe treatment procedures for the comparison group, particu-
larly if using an attention-control or an education/information
comparison or other comparison group that requires a speciﬁc
approach for participant interactions with trained research
personnel. A sample MOOP table of contents is in Appendix A7.
Demographics/participant characteristics
For behavioral intervention trials, the general characteristics of
participants that at a minimum, should be collected at enrollment
include age, sex, race/ethnicity, height, weight, body mass index
(BMI), years of formal education, tobacco use, employment status,
occupation, comorbid illnesses, and past/current treatments for OA.
These characteristics may be the basis of important inclusion/
exclusion criteria for a trial, may be critical factors that inﬂuence
the success of an intervention (moderators of treatment effects), or
may help determine whether intervention and control groups are
comparable after randomization. BMI or comorbid illnesses may
affect the success of exercise or weight loss interventions and
should be a part of enrollment and data analysis considerations.
Comorbid conditions that should be assessed are chronic diseases
such as diabetes, hypertension, cardiovascular disease, neurological
disorders, depression, concomitant rheumatologic disease, and
prior injury or surgery to the joint of interest. Additional conditions
may be of interest depending on the goals of the study. Information
on past and current pharmacologic and non-pharmacologic treat-
ments for OA may inﬂuence study outcomes or be relevant inclu-
sion/exclusion criteria. Behavioral intervention trials of OA may
consider concomitant rheumatologic conditions as exclusion
criteria.
Diagnosis of OA
The diagnosis of OA should be described in the study protocol
using validated criteria, such as the classiﬁcation criteria of the
American College of Rheumatology (ACR)8,9, which considers
symptoms, radiographic evidence, and laboratory results. OA can be
classiﬁed as primary or secondary and distinguished as unilateral or
bilateral. Except for pragmatic study designs, the study population
in most studies should be homogenous with regard to these cate-
gories. In behavioral intervention studies for diet and/or exercise
that focus on symptom or function outcomes, clinical criteria for OA
without radiography or laboratory analysis may be appropriate.
ACR clinical criteria for diagnosis of knee OA include frequent knee
pain plus at least three of the following six: age50 years; morning
stiffness <30 min/day; crepitus; bony tenderness; bony enlarge-
ment; no palpable warmth (the latter features are determined by
physical examination, preferably by a trained and certiﬁed
examiner).
Many clinical trials limit assessment of OA to a single primary
symptomatic joint site, such as the knee or the hip, though some
research teamsmight consider it appropriate to include other joints
that may be involved. Limiting inclusion to people with a single
symptomatic joint facilitates determining more clearly the inter-
vention effect on the index joint by eliminating potentialconfounders from other compromised joints. Alternatively, deter-
mining the effects of an intervention on multiple symptomatic
joints (e.g., OA of the hip and knee) may be more representative of
the typical OA patient. This would be particularly relevant for a
pragmatic trial.
OA severity
Radiographs or images of joints to identify OA severity may not
be necessary in behavioral intervention trials for exercise and/or
weight loss where the study outcomes tend to be symptoms or
function. More often, severity of OA in these trials is based on the
magnitude of symptoms. Most OA patients enrolled in exercise and/
or weight loss clinical trials have mild to moderate knee pain on
most days of the week. Disease severity based on radiographs or
images may be necessary for considering inclusion or exclusion
from a study. For example, many behavioral intervention studies of
OA exclude patients with high levels of pain or severe radiographic
disease (such as a KL grade 4)10. The rationale for omitting patients
with either severe pain or severe disease includes the likelihood
that exercise and/or diet will have little effect, as most of these
patients are candidates for knee replacement surgery, and the
belief that exercise and/or diet may bemore effective in slowing the
progression of disease and reducing pain in people with mild to
moderate disease.
Baseline measures
Since symptoms and function are often the main outcomes of
interest in behavioral intervention studies of diet or exercise in-
terventions, collecting data on these aspects at baseline, as well as
at follow-up visits, is critical. Reliable and valid measures should be
used, and for functional outcomes, self-reported and performance-
based measures should be included. For trials of patients with knee
or hip OA, examples of symptom measures are the Visual Analog
Scales for pain, stiffness and fatigue, the pain and stiffness subscales
of the Western Ontario and McMasters Universities (WOMAC) OA
index for hip and knee OA11, and the pain and other symptoms
subscales of the Knee injury and Osteoarthritis Outcome Score
(KOOS)12,13 and Hip disability and Osteoarthritis Outcome Score
(HOOS)14. Duration of symptoms should be collected since this may
play a role in the ability of the participant to beneﬁt from the
intervention.
Self-reported measures of function include OA-speciﬁc in-
struments such as the function subscale of the WOMAC and the
activities of daily living of the KOOS and HOOS. Other measures not
speciﬁc to OA that may be useful in an OA population include the
Physical FunctioneMobility questionnaire from the NIH-supported
Patient Reported Outcomes Measurement Information System
(PROMIS®). Performance-based measures of physical function
include the recommended set by theOsteoarthritis Research Society
International (OARSI) for people diagnosed with hip or knee OA
(http://www.oarsi.org/research/physical-performance-measures).
The minimal core set of physical function measures should include
the 30-s chair stand, 40-m fast-paced walk, and stair negotiation.
Two further tests, the timed up-and-go and 6 min walk are also
highly recommended, depending on the research setting to mea-
sure ambulatory transitions and aerobic capacity15.
Some psychosocial characteristics may inﬂuence the effective-
ness of a diet or exercise intervention, acting as mediators or
modiﬁers, or these characteristics may be altered by the interven-
tion. In either case, psychosocial variables, such as depression,
anxiety, pain coping strategies, pain catastrophizing, fear of
movement, pain acceptance, self-efﬁcacy, and outcome expecta-
tions should be collected at baseline and subsequent visits.
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The inclusion and exclusion criteria should reﬂect the study
population of interest and be unambiguous. Participants who have
the potential to beneﬁt from the behavioral intervention should be
considered for inclusion in the study; they should be included if
they have baseline symptoms or functional outcomes that are likely
to achieve a clinically important difference at follow-up if the
intervention is successful (such as those with mild to moderate OA
severity). Exercise interventions would generally include people
who are sedentary; weight loss interventions e people who are
overweight or obese. Patients should be excluded from study
participation if they have individual factors that would substan-
tially affect the outcome measures, such as painful concomitant
rheumatologic conditions or neurological disorders that impair
function. Furthermore, if patients are receiving or are scheduled to
receive other treatments for their OA during the study period (e.g.,
joint injection, joint replacement surgery) the ability to detect the
effect of the study intervention may be diminished; these treat-
ments may be a reason to exclude individuals from the trial. Par-
ticipants at considerable risk for AEs should be excluded. Aerobic
exercise interventions in an older population may require admin-
istering a graded exercise test to exclude people with signiﬁcant
cardiovascular disease.
Behavioral pragmatic trials have less restrictive inclusion/
exclusion criteria than efﬁcacy trials. They use more lax criteria to
include participants with heterogeneous characteristics similar to
those seen in clinical practice (e.g., patients with multiple joint
involvement, patients with prior joint replacement surgery in one
joint but pain in other joints) may be appropriate to include in a
pragmatic trial because they are representative of the patients that
are often seen in the general population. In addition to themore lax
inclusion criteria, pragmatic trials use ﬂexible intervention regi-
mens and active control treatment groups or usual care groups, if
examining comparative effectiveness.
Study population
The source of the patient population (e.g., clinic-based, com-
munity-based, hospital-based) should be deﬁned in the protocol.
Considerable controversy exists regarding the use of broad vs
narrow patient eligibility criterion. Broad patient eligibility allows
for generalizable application of positive results; however, because
of the greater variability, broad patient eligibility increases the
sample size of the study population required to demonstrate clin-
ically and statistically signiﬁcant differences, and may mask the
presence of subsets of patients receiving beneﬁt (unless extensive
stratiﬁcation is performed). Patient eligibility should deﬁne speciﬁc
populations and, where appropriate, stratiﬁcation of subgroups
should be employed within studies for secondary endpoints of in-
terest. Examples of high-risk groups that might be considered for
inclusion in behavioral studies include obese participants with co-
morbid conditions such as diabetes or heart disease that would
require special attention by the intervention staff. If included, safety
rules should be in place that would be sufﬁcient to accommodate
these high risk groups.
General physical examination
A general physical examination should be performed at the
onset of the study to identify the presence of conditions that may
exclude participation. The elements of the examwill be dictated by
the goals and topic of the intervention.Informed consent
Guidelines for information to be contained in the Informed
Consent statement should be in accordance with the Declaration of
Helsinki (http://www.wma.net/en/30publications/10policies/b3/).
Patient participation requires understanding and completion of an
informed consent document that has been approved by the
appropriate IRB.Conduct of the study
This section details the procedures used during a lifestyle diet
and/or exercise randomized clinical trial, exclusive of individual
outcome variables.Study design
The study should include at least one screening (usually via
phone or alternatively online or in person) and one baseline visit. At
least one face-to-face visit enhances the validity of baseline data,
assures that the patients fulﬁll entry criteria, may be used to help
reduce noncompliance for efﬁcacy trials, and is an opportunity to
collect biological specimens. As personal communication technol-
ogy advances interventions may be delivered solely online or with
smartphones or similar devices. The Healthy Weight for Life pro-
gram (www.healthyweightforlife.com.au) is an example of a
remotely delivered weight loss and exercise program that is sup-
ported by private health insurers.
Study enrollment can take two forms, one where patients are
randomized in the order in which they are enrolled (i.e., rolling
enrollment), or the other in which patients are enrolled in waves of
a set number of participants every few months. The beneﬁt of the
former method is a reduction in lag time between randomization
and the beginning of the intervention period. The latter method is
beneﬁcial in interventions delivered in group settings where there
is beneﬁt in promoting camaraderie and adherence among partic-
ipants assigned to a treatment in a given wave, but the time be-
tween randomization and the start of the intervention is longer and
increases the risk that eligible participants could decide not to
participate. Procedures are required to prevent contamination or
personal communication between intervention group and control
group participants that could bias the results. Furthermore, a
“group” variable (i.e., the particular group the patient was in) needs
to be included in data analysis as a factor to be considered. At each
visit, vital signs (at a minimum blood pressure, heart rate, and
weight) should be recorded and a report of adverse experiences
obtained. To minimize unwanted sources of variation in patient
assessment due to possible variability in symptoms throughout the
day and to the extent possible, the same examiner should assess the
same patient at each visit, at the same time of day throughout the
duration of the trial.Primary study outcome
Efﬁcacy studies of OA should preferably identify a single clearly
deﬁned primary outcome. The choice will depend upon the nature
of the desired effect and the study objectives. An alternative
approach might involve the use of several primary outcome vari-
ables (e.g., one clinical and one mechanistic). With the latter
approach, adjustments to the signiﬁcance level are generally
required for multiple analyses performed (Section E, Outcome
measures).
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The inclusion of one or more secondary outcome variables will
strengthen the study design. Collection of information for the
secondary outcome variables should not interferewith collection of
data for the primary outcome variable.
Minimally clinically important improvement (MCII) and minimally
clinically important difference (MCID)
Determining the clinical importance of a treatment effect is
critical. The MCII is the minimal change required from baseline to
follow-up to consider a statistically signiﬁcant outcome also
clinically signiﬁcant. The only responder criteria for pain and
function in randomized clinical trials of OA that is recommended
by recognized governing bodies, the Outcome Measures in
Rheumatology (OMERACT) -OARSI criteria, indicate a minimum
of 20% improvement from baseline in both pain and function or a
50% improvement in either pain or function. However, the MCII
does not take into consideration the difference in outcomes be-
tween intervention and control groups. The MCID accomplishes
this by setting standards in improvements relative to a control
group. A MCID is the smallest difference in score that is perceived
by patients as beneﬁcial and would mandate a change in the
patient's management. There are many suggestions on what
statistic best represents a MCID. Crosby et al.16 discuss this in
depth and note one standardized benchmark is an effect size of
0.5, approximately equivalent to 0.5 times the standard devia-
tion. Effect sizes are efﬁcient, widely accepted, and have well-
accepted benchmarks based upon external anchors. Samsa
et al.17 suggest an effect size of 0.2 (or .2 SD) as a MCID. Unfor-
tunately, there is little empirical evidence in the OA literature to
address this issue. Caution should be used in distinguishing MCII
from MCID data, the latter being more relevant in randomized
clinical trials.
Examiner
In behavioral studies an exercise or nutrition interventionist
has frequent contact with participants, thus double-blinded
studies are difﬁcult to design. Behavioral intervention trials are
usually single blinded in which the examiner (assessor) is blinded
to group assignment. Great care must be taken to inform partici-
pants not to reveal group assignment during testing. Some con-
troversy exists regarding weight loss studies in which an extreme
weight loss that occurs between baseline and follow-up testing
would be obvious to an examiner. For example, this may occur in a
study involving bariatric surgery. One possible solution in such an
extreme case would include utilizing different examiners for
baseline and follow-up testing. This could still be problematic, in
that the control group would clearly be much heavier than the
bariatric surgery group, even to the uninitiated eye. Another so-
lution would be conducting assessments by phone or web-based
questionnaires.
Social cognitive theory (SCT) in diet and/or exercise interventions
SCT is the most common theoretical model used to guide diet
and/or exercise interventions18,19. It is based on three constructs:
self-efﬁcacy expectations, outcome expectations, and incentives.
Self-efﬁcacy expectations represent individuals' beliefs that they
can act to satisfy situational demands so as to accomplish a given
goal (e.g., control pain, engage in activities of daily living). Such
beliefs are determined by prior behavior, physical symptoms (e.g.,
pain, fatigue), appetite, affect, and social/environmental factors.The physical activity literature has studied self-efﬁcacy in relation
to the ability to perform functional tasks or physical challenges of
varying difﬁculty, and under various environmental, social, or
emotional stressors.
Outcome expectations refer to the belief that certain outcomes
can be achieved. Some people simply do not know the health
effects of losing weight or exercising and others do not have
realistic expectations about how much improvement they can
attain.
Incentives refer to the value people associate with outcomes.
Knowing how much participants' value controlling their disability;
the dissatisfaction differential between the goal and current levels;
and the commitment to competing behaviors, such as re-
sponsibilities to families or friends, is relevant.
Behavioral interventions such as exercise and diet that are based
on SCT often use group interventions to increase: (1) knowledge
about ﬁtness, weight loss, and disability and change outcome ex-
pectancies; (2) self-efﬁcacy through modeling, mastery experi-
ences, and feedback, (3) changes in exercise and dietary behavior;
(4) incentives, through assessment and feedback on behaviors/
outcomes; and (5) self-regulatory skills through training in coping
skills as well as goal setting and problem solving to initiate change,
overcome obstacles to change, and maintain change.
Patient adherence and retention
It is essential for studies that strategies be employed to maxi-
mize and document patient compliance. The method of commu-
nication and time spent with participants should be standardized
as much as possible without jeopardizing the relationship with the
participant.
Adherence is a particular problem for long-term behavioral
interventions, particularly if participants do not readily perceive
beneﬁt from continued participation or experience other barriers.
Some known barriers from physical activity studies for older
adults with knee OA include: symptoms such as pain and fatigue,
non-OA health issues, lack of support or discouragement from
close others, work-related conﬂicts, transportation issues, and a
busy schedule. Protocols should be designed to address these
barriers, while providing mastery experiences and a positive study
environment. Speciﬁcally, protocols should evolve from SCT, group
dynamics literature, and resiliency theory. Selecting participants
who do not expect to leave the area during the study and using
cognitive/behavioral management strategies guided by SCT to
structure a positive exercise or dietary therapy environment have
proven effective20. Retention rates of 80% and adherence rates
60% for long term clinical trials (minimum of 12 months) are
desirable.
Interventionists should be trained in standardized, state-of-
the-art behavioral techniques to enhance adherence. These
methods, consistent with the social cognitive framework, include
frequent contact during the intervention and establishment of a
personal commitment to the project. From the onset, the
importance of regular attendance should be emphasized and
encouraged. Adherence enhancement strategies can incorporate
various approaches including: (1) the importance of regular
attendance. Participants who miss a single intervention session
should be immediately contacted to determine the reason why
they missed and to provide empathic support for their continued
participation; (2) for participants who miss more than one ses-
sion, a “toolbox” approach to individually tailor adherence stra-
tegies via telephone calls or in-facility discussions; and (3) the
interventionist should meet with their respective groups often at
the beginning of the intervention to discuss barriers to
attendance.
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protocols
Exercise and weight loss (diet) interventionist qualiﬁcations
vary widely and include nurses, physical therapists, and American
College of Sports Medicine (ACSM) certiﬁed trainers. At a mini-
mum, the lead interventionist should have a bachelor's degree in
health and exercise science or a related ﬁeld with a Master's degree
preferable, the appropriate ACSM certiﬁcation, training in behav-
ioral techniques (see section Social Cognitive Theory in Diet and/or
Exercise Interventions), Basic Cardiac Life Support (CPR), and NIH-
approved protection of human subjects. The lead diet or nutrition
councilor should also be trained in behavioral techniques and have
at a minimum a bachelor's degree in nutrition, public health, ex-
ercise science, or health education with a Master's degree
preferred. CPR certiﬁcation and experience working with weight-
loss and wellness programs is preferable. These interventionists
should have expertise in exercise, nutrition, and SCT.
To ensure the quality and consistency of the intervention pro-
tocol, efforts should be made to enhance interventionist compe-
tence and adherence. Interventionist competence refers to the
delivery of an intervention in away that is skilled and responsive to
patient needs. To assess competence, raters score a randomly
selected subset (e.g., 20%) of the tapes of sessions for each treat-
ment condition. Procedures for assessing interventionist compe-
tence have been discussed in the literature21. Typically, protocol
adherence criteria are developed for each session, and then raters
score audiotapes and videotapes of each session for satisfactory
ﬁdelity (deﬁned usually as 90% or more of the maximum possible
rating).
Use of concomitant medications
It is impractical to expect patients to participate in a long-term
trial without some potential for use of rescue medications for pain.
For long-term trials, use of concomitant medication should be
permitted on a limited basis. An example may be the use of acet-
aminophen (or paracetamol) for escape analgesia (up to 3 gm/day
with modiﬁcations in the setting of kidney or liver disease). To
remove the effect of an analgesic drug on study outcomes, any
escape medication should be discontinued in sufﬁcient time for the
clinical effects of the agent to disappear prior to assessment. Pro-
tocol design should include a record of the consumption of anal-
gesics, NSAIDs, and intra-articular (IA) injections, the latter which
could not be withdrawn prior to assessment of study outcomes.
AEs
An AE is any unplanned, unwanted event that occurs to a person
and is possibly related to the use of the protocol. While some AEs
may not appear related to the study, a relationship may not be
apparent until a number of reports accumulate. A SAE is deﬁned as
an AE that results in any of the following outcomes: death, life
threatening experiences, in-patient hospitalization or prolonged
hospital stay, or disabling or injurious event. All AEs and SAEs
should be recorded at each visit and between visits, as appropriate.
The date of onset, severity, a judgment with respect to the rela-
tionship between the AE and the intervention, treatment, duration,
and resolution of the AE should all be recorded. SAEs should be
reported to regulatory bodies within 24 h of the event. The prompt
reporting of AEs and SAEs should be emphasized to participants to
facilitate rapid reporting to regulatory bodies (e.g., IRB, DSMB).
Generally, there are few AEs in exercise studies; they usually
include relatively mild strains and muscle soreness, but potentially
more serious trips and falls.Alert values should be set for weight loss. A loss of >20% body
weight after 6 months or >30% after 12 months should trigger a
weight-related safety alert7. The participant should be interviewed
by the study medical director who will look for any potential
medical explanation for the rapid weight loss (such as signs or
symptoms of malignancy) and, if appropriate, refer the participant
to his/her primary care physician for further evaluation.
Protocol violation
Reasons for termination of a participant from the study due to
protocol violationmust be speciﬁed in the protocol. Intake of rescue
medications (other than those speciﬁcally prescribed), use of oral
or topical agents, or devices targeted toward pain relief during the
course of the study are causes for concern and should be discussed
by the investigators. Information on the use of such agents should
be obtained at each visit and recorded, and the patient should be
warned about such co-interventions.
Outcome measures for OA clinical trials
Instruments used to measure outcomes in OA clinical trials
should be valid, reliable, and responsive to change when such
measures exist. OA trials should use published instruments that
have been used in other studies, thus permitting comparison of
results across trials of different therapeutic interventions. The
study group was unanimous that exercise and diet behavioral
clinical trials in OA should include a core set of validated measures
as noted below. OARSI has recommended additional core measures
(http://www.oarsi.org/research/physical-performance-measures).
 Pain
 Physical function
 Patient global assessment
 Mobility (e.g., 6 min walk, 400 m walk)
Additional measures that are recommended include the
following:
 Health Related Quality of Life (strongly recommended)
 Physician global assessment
Optional measures for trials in OA include the following:
 Signs of inﬂammation: For non-pharmacologic clinical trials
interested in biomarkers, tests would include a blood draw to
examine serum inﬂammatory biomarkers and possibly a uri-
nalysis to examine OA biomarkers.
 Biologic markers
 Stiffness
 Presence of ‘ﬂares’
 Biomechanical measures of joint loading
 Analgesic consumption
Exclusion criteria generally include surgery on the primary
study joint; however, if the surgery occurs after randomization,
whether the participant is given the choice to continue is less
deﬁnitive. In keeping with intent-to-treat principles and with the
approval of the participant's personal physicians, investigators may
elect a priori to permit these participants to continue in the study.
Clinical measures to assess participant progress during the
trial are critical in monitoring adherence and safety. Since these
measures are usually performed by the interventionists and
therefore are not assessor blinded, they should not be part of the
study aims. Daily exercise logs should be completed by each
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tervals (e.g., daily, weekly, monthly). For aerobic exercises, heart
rate, perceived exertion, and pain level should be self-monitored
and recorded on the log. Strength training logs should include
weight, sets, repetitions for each exercise, and pain level. Seat
adjustment should be noted for all exercises performed on weight
machines.
Food records should be kept daily or several days each week
(e.g., two weekdays and one weekend day). The quality of these
records should be monitored closely by the interventionists.
Participant weigh-in should occur weekly, be performed by the
interventionists at the meeting site, and be administered in private.
A person's weight is a sensitive topic, thus care must be taken to
ensure conﬁdentiality. In the case of a home-based intervention,
self-monitoring should be veriﬁed periodically by the
interventionist.
Explanation of outcome measures
Pain
The degree of joint pain in the index joint(s) should be graded.
Pain should be recorded on a ﬁve-point Likert scale (e.g., none,
mild, moderate, severe, very severe), a 100 mm visual analogue
scale (VAS), or a 0e10 numeric rating scale (NRS). Questions about
pain should specify the time period that patients use in answering
the question (e.g., pain right now, pain over the past week). Com-
posite ratings (i.e., averaging a rating of pain now, pain at its worst
in the past week, and pain at its lowest in the last week) are
increasingly being used22,23. Alternatively, a validated pain instru-
ment is used (e.g., WOMAC pain subscale; KOOS pain subscale).
Pain-related psychological measures are increasingly being used
as outcome measures since they provide measures of relevance to
SCT and are often predictive and/or mediators of long-term
improvement. These include scales such as the Arthritis Self-
Efﬁcacy Scale24, the Pain Catastrophizing Scale25, and the Fear
Avoidance Beliefs Questionnaire26.
Function
The Attentional Function Index27 and the function subscale of
the WOMAC28 are validated and recommended for studies of OA of
the hip and knee. Other indices that have been used include the
Health Assessment Questionnaire (HAQ) disability index, and
Arthritis Impact Measurement Scales (AIMS)29,30.
Global status
Patient assessment of global status. The patient's assessment of his/
her global status should be measured using a Likert or VAS scale.
The optimal method by which this should be measured is not well
established. However, a standard question should be asked, e.g.,
‘Considering all of the ways your (joint site) OA affects you, how are
you doing (time frame)?’
Physician assessment of global status. A measure of the physician
assessment of global status may be required by some regulatory
agencies. There is no generally accepted method for measurement
of this variable. A question such as ‘Considering all information,
how is the patient's (joint site) OA today?’ should be used with a
VAS or Likert scale.
Performance-based measures
Performance-based measures that include such items as grip
strength (a good indicator of overall strength)31, time to walk a
speciﬁed distance (e.g., 400 m), and distance walked in a speciﬁed
time (e.g., 6 min) have been used extensively15.Quality of life scales
Measurement of health-related quality of life and utility based
measures at appropriate intervals is strongly recommended,
although these are not a part of the core set of measures. Examples
of health related quality of life instruments include the Medical
Outcomes Study, 36 question short form (SF-36)32, Sickness Impact
Proﬁle (SIP)33, Nottingham Health Proﬁle (NHP)34, and EuroQol35.
Examples of utility instruments include the Time Trade Off, the
Standard Gamble and Techniques and Feeling Thermometer and
the Health Utilities Index (HUI)36e39.
Inﬂammation
Studies demonstrate that low-grade inﬂammation plays a
pathophysiological role in OA. An inﬂammatory component asso-
ciated with OA can be detected in the circulation. Inﬂammatory
markers such as cytokines (interleukin-6, tumor necrosis factor
alpha) and the acute phase reactant C-reactive protein are higher in
persons with hip or knee OA compared to those without40e42.
Behavioral exercise and weight loss interventions have shown
signiﬁcant reductions in these cytokines; however, whether
inﬂammation constitutes a separate OA disease pathway or instead
is the downstream result of chronic excessive biomechanical stress
is debated43,44.
Biologic markers of OA disease
OA biomarkers, such as cartilage oligomeric matrix protein
(COMP), are being evaluated as potential surrogate measures of
joint disease activity. However, no studies have yet linked them
with disease progression as measured by MRI or quantitative (q)
MRI. Serum levels of the N-propeptide of type IIA procollagen as a
measure of type II collagen synthesis and urine levels of C-ter-
minal crosslinking telopeptide of type II collagen (CTX-II), a pu-
tative measure of type II collagen degradation, are commonly
analyzed using ELISA assays. For further discussion of the potential
role of biomarkers in OA, please see the section in this issue on this
topic.
Joint loading
Epidemiological and biomechanical data suggest that the addi-
tional mechanical stress that obesity places on weight-bearing
joints increases the risk of developing knee OA45. Gait analysis
techniques can estimate the loads on the lower extremity joints.
The most common variable used in OA studies is the external knee
adduction moment, a surrogate measure of knee joint loading that
is obtained using standard gait analysis software46. A more direct
measure of joint loading is obtained using musculoskeletal
modeling. Although modeling is a more complex calculation, it
estimates bone-on-bone forces, a more direct measure of joint
loading47.
Analgesic consumption
Participants should be administered a medication questionnaire
such as the one adapted from the Atherosclerosis Risk In Commu-
nities (ARIC) study and widely used in ﬁeld research48. It is
designed to obtain information about all prescription and over-the-
counter medicines and supplements used during the 2 weeks prior
to the interview (home or clinic). The participant provides the
interviewer with all medicine containers, and the interviewer
transcribes information from the containers onto the form.
Summary
The selection and proper collection of outcome measures are
critical to the success of a clinical trial. There are three general
categories from which to select; outcomes that are important to
the patient such as pain and function; mechanistic outcomes that
Table I
Suggested steps and considerations for conducting a clinical trial using a lifestyle diet and exercise intervention in patients with OA
Steps Considerations
Recruitment and enrollment of participants
Determine level of clinical trial - Choose:
 Phase 1 (test feasibility, acceptability, safety)
 Phase 2 (test efﬁcacy and safety under optimal conditions)
 Phase 3 (test efﬁcacy in large groups of people, monitor adverse effects)
 Pragmatic trial (test effectiveness in real-life routine practice conditions)
- Level chosen should be appropriate for study question
Create study protocol prior to participant
enrollment
- Must be developed prior to participant enrollment
- Include background information, speciﬁc objectives, research questions, study design, assessment
methods, and organization and methods of implementation of trial
Establish demographic and clinical characteristics
of participants to be collected
- Examples include age, sex, race, ethnicity, height, weight, BMI, years of formal education
Deﬁne diagnosis of OA - Select validated criteria that consider symptoms, radiographic/imaging evidence, or laboratory results
- Decide if OA assessment is limited to single primary joint or multiple joint sites
Deﬁne severity of OA - Disease severity frequently based on magnitude of symptoms
- Consider severity on radiography or images since this may determine inclusion/exclusion from the study
Select baseline measures - Choose reliable and valid measures, particularly ones that can detect change over time (minimally
clinically important improvement or difference)
- Primary outcomes likely will be symptoms (particularly pain) and function
- Both self-reported and performance-based functional measures should be considered
- Include psychosocial variables that may inﬂuence the effectiveness of the intervention
Determine inclusion/exclusion criteria - Select explicit criteria that reﬂect the study population of interest and level of clinical trial (e.g., Phase 1
vs Pragmatic Trial)
- Determine co-morbidities that are part of exclusion criteria (the fewer co-morbidities excluded the
more generalizable, but the more variability introduced)
Deﬁne source of the study population - Possible sources include clinics, hospitals, and the community
Include a general physical examination - Physical exam should be performed at study onset
- Should identify and evaluate severity of comorbid conditions that may exclude study participation
(see inclusion/exclusion criteria)
Establish informed consent procedures - Informed consent document must be prepared in accordance with the Declaration of Helsinki and
must be approved by appropriate IRB
Conduct of the study
Establish study timeline and procedures at
each encounter
- Should include screening encounter and baselines visit
- Study enrollment may be rolling enrollment or enrollment waves
- Train study staff to ensure data collection procedures are standardized
Choose primary and secondary study outcomes - Include single clearly deﬁned primary outcome and one or more secondary outcomes
Select measure of minimally clinically important
improvement or difference
- Essential to include for determining treatment effect
Determine methods for blinding - Important to blind the examiner to group assignment and inform participants to not reveal their
group to the examiner
Incorporate SCT in lifestyle modiﬁcation
assessment and intervention
- At a minimum assessments should assess constructs of self-efﬁcacy expectations, outcome expectations,
and incentives
- Use SCT to inform intervention development (e.g., use modeling, feedback to enhance learning)
Employ strategies to enhance participant
adherence and retention
- Use best practice methods such as frequent contact with participants during the study and the
establishment of personal commitments by the participant to the project and the study staff
to the participant
Establish interventionist qualiﬁcations,
competence, and adherence to protocols
- Depending on the lifestyle modiﬁcation intervention to be tested, the interventionist may need
expertise and/or background in exercise, nutrition or psychosocial theories (e.g., operant behavioral
and/or SCT).
Document use of concomitant medications - In long-term trials, use of concomitant medication should be documented on an ongoing basis.
Consider allowing use on a limited basis but recorded to account for its effect on study outcomes
Record adverse events at each visit
and between visits
- Deﬁne what constitutes a SAE
- For all adverse events, record date of onset, severity, relationship to the study intervention,
treatment, duration, and resolution
- Encourage participants to promptly report adverse events
- Report adverse events to regulatory bodies
Record protocol violations - Protocol should deﬁne types of protocol deviations.
- Protocol should include an assessment of reasons for termination of participant from study
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loads, inﬂammatory biomarkers); and structural outcomes that
document disease progression (e.g., X-ray and MRI). Collection of
these data by technicians who have had appropriate training
with documented excellent test-retest reliability and that are
blinded to group assignment reduces unwanted variability.
Additional concerns with data collection will appear as large
scale clinical trials trend toward remote data collection using the
internet and apps on smartphones. Table I summarizes the sug-
gested steps and considerations for conducting a clinical trial
using a lifestyle diet and/or exercise intervention in patients
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